In this article, we will discuss Olaparib (Clinical Trials Experience-7). So, let’s get started. There were 8 (4%) patients with adverse reactions leading to death, two were attributed to acute leukemia, and one each was attributed to COPD, cerebrovascular accident, intestinal perforation, pulmonary embolism, sepsis, and suture rupture. The median exposure to Olaparib capsules in these […]
Tag: Olaparib
In this article, we will discuss Olaparib (Clinical Trials Experience-6). So, let’s get started. Treatment of Advanced gBRCAm Ovarian Cancer After 3 or More Lines of Chemotherapy Pooled data (1) Treatment with Olaparib (capsule formulation) as monotherapy was studied in 223 patients (pooled from 6 studies) with gBRCAm advanced ovarian cancer who had received 3 […]
In this article, we will discuss Olaparib (Clinical Trials Experience-5). So, let’s get started. Adverse reactions led to dose interruptions in 35% of those receiving Olparib and 10% of those receiving placebo; dose reductions in 26% of Olparib and 4% of placebo; and discontinuation in 6% of Olparib and 2% in placebo.
In this article, we will discuss Olaparib (Clinical Trials Experience-4). So, let’s get started. The safety of Olaparib capsules as maintenance monotherapy was also evaluated in patients with platinum sensitive ovarian cancer who had received 2 or more previous platinum containing regimens in Study, a randomized, placebo-controlled, double-blind, multi-center study in which 264 patients received […]
In this article we will discuss Olaparib (Drug Interaction-1)
In this article, we will discuss Olaparib (Clinical Trials Experience-3). So, let’s get started. Dose interruptions due to an adverse reaction of any grade occurred in 45% of patients receiving Olaparib and 18% of those receiving placebo; dose reductions due to an adverse reaction occurred in 27% of Olaparib patients and 3% of placebo patients. […]